Solid Biosciences
SLDB
34 hedge funds and large institutions have $85.3M invested in Solid Biosciences in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 10 increasing their positions, 17 reducing their positions, and 29 closing their positions.
4,220% more call options, than puts
Call options by funds: $216K | Put options by funds: $5K
1,151% more capital inflows, than outflows
Capital inflows: $74.1M | Capital outflows: $5.93M
41% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 17
41% less funds holding
Funds holding: 58 → 34 (-24)
56.22% less ownership
Funds ownership: 56.22% → 0% (-56%)
79% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Perceptive Advisors
New York
|
+$17.1M |
| 2 |
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$17.1M |
| 3 |
RA Capital Management
Boston,
Massachusetts
|
+$17.1M |
| 4 |
Camber Capital Management
Boston,
Massachusetts
|
+$9.3M |
| 5 |
Laurion Capital Management
New York
|
+$5.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Suvretta Capital Management
New York
|
-$4.2M |
| 2 |
Oasis Management Company
Grand Cayman,
Cayman Islands
|
-$373K |
| 3 |
BlackRock
New York
|
-$296K |
| 4 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$187K |
| 5 |
Renaissance Technologies
New York
|
-$103K |
SLDB Hedge Fund Activity: Q4 2022 in Review
34 of the 6,242 institutional investors tracked by Wall St. Rank reported a position in Solid Biosciences (SLDB) for Q4 2022, worth a combined $85.3M — up 155% from $33.4M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of SLDB and 6 opened new positions — a net loss of 23 holders — while 17 trimmed existing stakes and 10 added.
The largest buyer was Perceptive Advisors, adding an estimated $17.1M. The largest seller was Suvretta Capital Management, exiting entirely with an estimated $4.2M sold.
- 34 institutional investors held Solid Biosciences (SLDB) as of Q4 2022, down from 58 in Q3 2022.
- Funds reported $85.3M of Solid Biosciences stock for Q4 2022, up 155% quarter-over-quarter.
- 6 funds opened new Solid Biosciences positions in Q4 2022 and 29 closed out, a net change of -23 holders.
- The largest Solid Biosciences buyer in Q4 2022 was Perceptive Advisors, an estimated $17.1M added.
- The largest Solid Biosciences seller in Q4 2022 was Suvretta Capital Management, an estimated $4.2M sold.
Based on aggregated 13F filings for Q4 2022.